Search Result

Results for "

myocardial infarction model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldehyde Dehydrogenase (ALDH) (1) AMPK (2) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (1) Apoptosis (2) ATP Synthase (1) Bacterial (1) Biochemical Assay Reagents (1) Bradykinin Receptor (1) Calcium Channel (1) CaMK (1) Cytochrome P450 (2) Drug Isomer (1) Dynamin (2) Endogenous Metabolite (3) Endothelin Receptor (1) ERK (1) Ferroptosis (1) FGFR (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (2) HIV (2) HIV Protease (2) HSP (1) Interleukin Related (1) JAK (1) Keap1-Nrf2 (1) MMP (1) Myosin (1) NF-κB (1) NOD-like Receptor (NLR) (1) P-glycoprotein (2) P2Y Receptor (1) p38 MAPK (1) PKC (2) Prostaglandin Receptor (1) Pyroptosis (1) Reference Standards (1) SARS-CoV (2) STAT (1) TNF Receptor (2) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (21) Infection (3) Inflammation/Immunology (7) Metabolic Disease (4) Neurological Disease (5)

By Targets:

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (2)

Angiotensin-converting Enzyme (ACE) (3)

Antibiotic (1)

Apoptosis (2)

ATP Synthase (1)

Bacterial (1)

Biochemical Assay Reagents (1)

Bradykinin Receptor (1)

Calcium Channel (1)

CaMK (1)

Cytochrome P450 (2)

Drug Isomer (1)

Dynamin (2)

Endogenous Metabolite (3)

Endothelin Receptor (1)

ERK (1)

Ferroptosis (1)

FGFR (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (2)

HIV (2)

HIV Protease (2)

HSP (1)

Interleukin Related (1)

JAK (1)

Keap1-Nrf2 (1)

MMP (1)

Myosin (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

P-glycoprotein (2)

P2Y Receptor (1)

p38 MAPK (1)

PKC (2)

Prostaglandin Receptor (1)

Pyroptosis (1)

Reference Standards (1)

SARS-CoV (2)

STAT (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

By Research Areas:

Cancer (8)

Cardiovascular Disease (21)

Infection (3)

Inflammation/Immunology (7)

Metabolic Disease (4)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108841

Raleukin 50+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-16657

TAPI-1 10+ Cited Publications	MMP NF-κB Apoptosis TNF Receptor	Inflammation/Immunology Cancer
TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .

HY-17367

Atazanavir Maximum Cited Publications 13 Publications Verification BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-Z0478

(-)-Limonene 1 Publications Verification (S)-(-)-Limonene	Bacterial Antibiotic CaMK	Infection Cardiovascular Disease Metabolic Disease
(-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca ²⁺) and Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .

HY-B0592

Trandolapril RU44570	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-141510

myo-Inositol trispyrophosphate hexasodium ITPP hexasodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 13 Publications Verification BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Drug Isomer	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
(E/Z)-Polydatin ((E/Z)-Piceid) is a mixture of the E/Z configurations of Polydatin (HY-N0120A). Polydatin can be isolated from Polygonum cuspidatum, grapes, peanuts, red wine, hop pellets, cocoa-containing products and chocolate products. Polydatin exhibits multiple biological properties, such as anti-platelet aggregation, anti-low-density lipoprotein oxidation, cardioprotective activity, anti-inflammatory and immunomodulatory functions. Polydatin shows favorable cytotoxic effects against various tumor cell lines, including cervical cancer cells, liver cancer cells, and nasopharyngeal carcinoma cells .

HY-149662

TMDJ-035	Calcium Channel ATP Synthase Myosin	Cardiovascular Disease
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC₅₀ of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca ²⁺ transients. TMDJ-035 decreases ATP content and intracellular Ca ²⁺ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .

HY-168894

CT-1	Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .

HY-P6437A

Drp1 peptide inhibitor P110 TFA	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-176716

ALDH2 activator 1	Aldehyde Dehydrogenase (ALDH)	Cardiovascular Disease
ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI) .

HY-106262B

Delcasertib hydrochloride 3 Publications Verification KAI-9803 hydrochloride; BMS-875944 hydrochloride	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-141510A

myo-Inositol trispyrophosphate hexa-triethylamine ITPP hexa-triethylamine	Biochemical Assay Reagents HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
myo-Inositol trispyrophosphate (ITPP) hexa-triethylamine is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate hexa-triethylamine is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate hexa-triethylamine enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate hexa-triethylamine can be used in the study of cardiovascular disease and cancer .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-106262

Delcasertib KAI-9803; BMS-875944	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-164853

Kanglexin	Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

HY-105209

Pirsidomine	Endogenous Metabolite	Cardiovascular Disease
Pirsidomine is a nitric oxide donor. Pirsidomine is a sydnonimine compound. Pirsidomine can transform into a nitric oxide-releasing metabolite in vivo. Pirsidomine prevents occlusion-induced increase in flow in the non-occluded circumflex coronary artery and significantly reduces the blood flow in non-ischemic areas in myocardial infarction dog model. Pirsidomine can be studied in research on cardiovascular diseases .

HY-175675

P2Y1 antagonist 4	P2Y Receptor Keap1-Nrf2	Cardiovascular Disease Neurological Disease
P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca ²⁺ increase (IC₅₀ = 1.95 μM) and platelet aggregation (IC₅₀ = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .

HY-B0592R

Trandolapril (Standard) RU44570 (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0592A

Trandolapril hydrochloride RU44570 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-118945

FR191413	Prostaglandin Receptor Bradykinin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FR191413 is a selective bradykinin B2 receptor agonist that stimulates prostaglandin E2 production in WI-38 cells and activates BK B2 receptor-mediated pathways such as vasodilation and organ protection. FR191413 competitively binds to [ ³H]-BK in guinea pig ileum (GPI) membranes and CHO cells transfected with the human BK B2 receptor, with IC₅₀ values of 20.0 nM and 2.60 nM, respectively. FR191413 can be used in research related to cardiovascular diseases and diabetes, including hypertension, myocardial hypertrophy, myocardial infarction, arrhythmias, and diabetic nephropathy .

Cat. No.	Product Name	Target	Research Area